Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 120,787 shares of the biopharmaceutical company’s stock after buying an additional 9,002 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $55,079,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ALNY. Sumitomo Life Insurance Co. boosted its position in Alnylam Pharmaceuticals by 49.5% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 3,167 shares of the biopharmaceutical company’s stock valued at $1,444,000 after acquiring an additional 1,049 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 31.9% during the 3rd quarter. Intech Investment Management LLC now owns 5,812 shares of the biopharmaceutical company’s stock worth $2,650,000 after purchasing an additional 1,404 shares during the last quarter. Fox Run Management L.L.C. boosted its position in Alnylam Pharmaceuticals by 16.0% during the third quarter. Fox Run Management L.L.C. now owns 1,465 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 202 shares in the last quarter. Waddell & Associates LLC bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $464,000. Finally, Greenland Capital Management LP grew its stake in Alnylam Pharmaceuticals by 95.9% in the third quarter. Greenland Capital Management LP now owns 1,959 shares of the biopharmaceutical company’s stock valued at $893,000 after purchasing an additional 959 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ:ALNY opened at $332.92 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The stock has a market cap of $44.15 billion, a price-to-earnings ratio of 194.69 and a beta of 0.35. The business has a 50-day moving average price of $360.54 and a 200-day moving average price of $418.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the company posted ($0.65) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on ALNY shares. Raymond James Financial reissued an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target on the stock. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,578 shares of company stock valued at $12,416,105 over the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.